European regulators are accusing Johnson & Johnson of illegally paying another company to delay the availability of a generic version of a product – in the process denying cancer patients access to a less expensive source of a drug that eases severe pain.
According to a story in the New York Times, the product at issue is a transdermal patch used to deliver the drug fentanyl through the skin. Antitrust authorities ...
continue reading...